BERLIN, Aug 1 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab will invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt, where ...
Hosted on MSN
Sanofi is transferring its global expertise in insulin production to Saudi Arabia, aligning with Vision 2030 program
As Saudi Arabia moves toward healthcare self-sufficiency under Vision 2030, the localization of vital pharmaceutical manufacturing has become a critical priority. In a major step forward, Sanofi, ...
Millions of patients rely on insulin. But with new drugs, some have been able to lower their doses or stop taking it altogether. By Dani Blum For over 20 years, Betsy Chadwell carried her insulin pens ...
Fresh hope for type 1 diabetes as daily pill that slows onset confirms promise at two-year follow-up
In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, ...
SHANGHAI, Dec 2 (Reuters) - Sanofi plans to invest around 1 billion euros ($1.05 billion) to build a new insulin production base in Beijing, which will mark the French drugmaker's largest single ...
People with type 1 diabetes must constantly rely on insulin injections or pumps, usually for the rest of their life after diagnosis. The autoimmune disease destroys the cells that produce the hormone, ...
In a medical first, researchers report that they have implanted CRISPR-edited pancreas cells into a person with type 1 diabetes. The cells pumped out sugar-regulating insulin for months — without the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback